Laura Kulik is a Gastroenterology physician affiliated with Northwestern University. OpenAlex indexes 240 publications with 31,352 citations (h-index 71); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Gastroenterology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
680 N Lake Shore Dr
Suite 1000
Chicago, IL 606114546
Telephone
312-695-9797Registry record last updated 8 Jul 2007.
Clinical trials
- Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
Sponsor: Northwestern University
- Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)
Sponsor: Northwestern University
- Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202511 payments
- Sirtex Medical IncProgram year20252 payments
- Novo Nordisk IncProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
37.8%Bile Acid18.9%Ursodiol100%Part D≥19 patientsRifamycin Antibacterial12.6%Xifaxan100%Part D<11 patients+ 1 more class in this area
Cardiovascular
27.2%Loop diuretic12.3%Furosemide67%Bumetanide33%Part D<11 patientsAldosterone antagonist (MRA)10.6%Spironolactone100%Part D≥14 patients+ 1 more class in this area
Anti-infectives
19.8%Nucleoside and nucleotide reverse transcriptase inhibitors15.5%Vemlidy54%Tenofovir Disoproxil Fumarate46%Part D<11 patientsHepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor4.3%Epclusa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Nature Reviews Gastroenterology & Hepatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University
Philip Greenland, MD
Northwestern University
Peter Kahrilas, MD
Northwestern University
Philip Gorelick, MD
Northwestern University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”